Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.
Also called NCT01534962
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 241 participants
- Sponsor
- Menarini Group
- Registry
-
NCT01534962 -
2011-002789-18
-
- Other papers using this trial's data
- Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany, Italy, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01534962. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-08-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
- Acronym
- RAFFAELLO
- Condition
- Persistent Atrial Fibrillation
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Menarini Group
Record details
- Record id
cardio:ct-nct01534962- Content hash
ee4ffb95b16bb87fd355d5350bab5907fcd4b97851299b08f4805a6900363eb2